Discovery of a Novel, Highly Potent and Orally Bioavailable Pyrrolidinone Indole Series of Irreversible Myeloperoxidase (MPO) Inhibitors
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Discovery of a Novel, Highly Potent and Orally Bioavailable Pyrrolidinone Indole Series of Irreversible Myeloperoxidase (MPO) Inhibitors
Authors
Keywords
-
Journal
BIOCHEMICAL PHARMACOLOGY
Volume -, Issue -, Pages 115418
Publisher
Elsevier BV
Online
2023-01-21
DOI
10.1016/j.bcp.2023.115418
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of myeloperoxidase and oxidant formation in the extracellular environment in inflammation-induced tissue damage
- (2021) Clare L. Hawkins et al. FREE RADICAL BIOLOGY AND MEDICINE
- Discovery of a novel indole pharmacophore for the irreversible inhibition of myeloperoxidase (MPO)
- (2020) Anup Patnaik et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Early clinical experience with AZD4831, a novel myeloperoxidase inhibitor, developed for patients with heart failure with preserved ejection fraction
- (2020) Karin Nelander et al. CTS-Clinical and Translational Science
- A patent review of myeloperoxidase inhibitors for treating chronic inflammatory syndromes (focus on cardiovascular diseases, 2013-2019)
- (2020) Jalal Soubhye et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Population Pharmacokinetic Modeling With Enterohepatic Circulation for AZD3241 in Healthy Subjects and Patients With Multiple System Atrophy
- (2018) Xiao Tong et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Discovery of 1-((6-Aminopyridin-3-yl)Methyl)-3-(4-Bromophenyl)Urea as a Potent, Irreversible Myeloperoxidase Inhibitor
- (2018) Martin L. Marro et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- The development of myeloperoxidase inhibitors
- (2018) Semira Galijasevic BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- An exploratory look at NETosis in atherosclerosis
- (2016) Chiara Mozzini et al. Internal and Emergency Medicine
- Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson’s disease
- (2015) Aurelija Jucaite et al. BRAIN
- Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases
- (2015) Roger B. Ruggeri et al. JOURNAL OF MEDICINAL CHEMISTRY
- Failure of Neuroprotection Despite Microglial Suppression by Delayed-Start Myeloperoxidase Inhibition in a Model of Advanced Multiple System Atrophy: Clinical Implications
- (2015) Christine Kaindlstorfer et al. NEUROTOXICITY RESEARCH
- Development of rapid multistep carbon-11 radiosynthesis of the myeloperoxidase inhibitor AZD3241 to assess brain exposure by PET microdosing
- (2015) Peter Johnström et al. NUCLEAR MEDICINE AND BIOLOGY
- Myeloperoxidase deficiency preserves vasomotor function in humans
- (2011) Tanja K. Rudolph et al. EUROPEAN HEART JOURNAL
- Plasma myeloperoxidase level and peripheral arterial disease
- (2011) Helmuth Haslacher et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- 2-Thioxanthines Are Mechanism-based Inactivators of Myeloperoxidase That Block Oxidative Stress during Inflammation
- (2011) Anna-Karin Tidén et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Human myeloperoxidase in innate and acquired immunity
- (2010) Juergen Arnhold et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- A new easy method for specific measurement of active myeloperoxidase in human biological fluids and tissue extracts
- (2009) T. Franck et al. TALANTA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now